WO2003051927A3 - Production of f(ab')2 fragments in mammalian cells - Google Patents
Production of f(ab')2 fragments in mammalian cells Download PDFInfo
- Publication number
- WO2003051927A3 WO2003051927A3 PCT/NL2002/000841 NL0200841W WO03051927A3 WO 2003051927 A3 WO2003051927 A3 WO 2003051927A3 NL 0200841 W NL0200841 W NL 0200841W WO 03051927 A3 WO03051927 A3 WO 03051927A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fragments
- production
- mammalian cells
- cells
- antibody fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ533332A NZ533332A (en) | 2001-12-17 | 2002-12-17 | Efficient production of F(AB')2 fragments in mammalian cells |
SI200230701T SI1456238T1 (en) | 2001-12-17 | 2002-12-17 | Production of f(ab')2 fragments in mammalian cells |
US10/499,298 US20050048038A1 (en) | 2001-12-17 | 2002-12-17 | Efficient production of f(ab')2 fragments in mammalian cells |
CA2470579A CA2470579C (en) | 2001-12-17 | 2002-12-17 | Production of f(ab')2 fragments in mammalian cells |
DE60226896T DE60226896D1 (en) | 2001-12-17 | 2002-12-17 | PREPARATION OF F (AB ') 2 FRAGMENTS IN TISSUE CELL |
AU2002353662A AU2002353662B2 (en) | 2001-12-17 | 2002-12-17 | Production of F(ab')2 fragments in mammalian cells |
EP02789019A EP1456238B1 (en) | 2001-12-17 | 2002-12-17 | Production of f(ab')2 fragments in mammalian cells |
DK02789019T DK1456238T3 (en) | 2001-12-17 | 2002-12-17 | Production of F (ab ') 2 fragments in mammalian cells |
US12/070,145 US7537916B2 (en) | 2001-12-17 | 2008-02-14 | Efficient production of F(ab')2 fragments in mammalian cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL0100917 | 2001-12-17 | ||
NLPCT/NL01/00917 | 2001-12-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10499298 A-371-Of-International | 2002-12-17 | ||
US12/070,145 Continuation US7537916B2 (en) | 2001-12-17 | 2008-02-14 | Efficient production of F(ab')2 fragments in mammalian cells |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003051927A2 WO2003051927A2 (en) | 2003-06-26 |
WO2003051927A3 true WO2003051927A3 (en) | 2003-11-20 |
Family
ID=19760784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2002/000841 WO2003051927A2 (en) | 2001-12-17 | 2002-12-17 | Production of f(ab')2 fragments in mammalian cells |
Country Status (11)
Country | Link |
---|---|
US (2) | US20050048038A1 (en) |
EP (1) | EP1456238B1 (en) |
AT (1) | ATE397019T1 (en) |
AU (1) | AU2002353662B2 (en) |
CA (1) | CA2470579C (en) |
DE (1) | DE60226896D1 (en) |
DK (1) | DK1456238T3 (en) |
ES (1) | ES2307807T3 (en) |
NZ (1) | NZ533332A (en) |
SI (1) | SI1456238T1 (en) |
WO (1) | WO2003051927A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
ATE384785T1 (en) | 2001-12-07 | 2008-02-15 | Crucell Holland Bv | PRODUCTION OF VIRUSES, VIRUS ISOLATES, AND VACCINES |
DE60226896D1 (en) | 2001-12-17 | 2008-07-10 | Crucell Holland Bv | PREPARATION OF F (AB ') 2 FRAGMENTS IN TISSUE CELL |
JP4865539B2 (en) | 2003-05-09 | 2012-02-01 | クルセル ホランド ベー ヴェー | E1 immortalized cell culture and method of culturing the culture to increase the yield of product obtained from the culture |
WO2019070108A1 (en) | 2017-10-02 | 2019-04-11 | Laboratorios Silanes S.A. De C.V. | High-performance process for producing poison-antidotes using f(ab')2 antibody fragments |
WO2023205656A2 (en) * | 2022-04-18 | 2023-10-26 | John Paul Ii Medical Research Institute | Immortalized cells for production of bioproducts, methods of producing bioproducts with an immortalized cell, and methods of making immortalized cells for production of bioproducts |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993006217A1 (en) * | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5591828A (en) * | 1989-06-22 | 1997-01-07 | Behringwerke Aktiengesellschaft | Bispecific and oligospecific mono-and oligovalent receptors, the preparation and use thereof |
EP1108787A2 (en) * | 1999-11-26 | 2001-06-20 | Crucell Holland B.V. | Production of vaccines |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4624846A (en) * | 1983-07-29 | 1986-11-25 | Immunomedics, Inc. | Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles |
DE3584341D1 (en) * | 1984-08-24 | 1991-11-14 | Upjohn Co | RECOMBINANT DNA COMPOUNDS AND EXPRESSION OF POLYPEPTIDES LIKE TPA. |
US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
DE69638058D1 (en) * | 1995-06-15 | 2009-11-26 | Crucell Holland Bv | Packaging systems for human recombinant adenoviruses for gene therapy |
SI1161548T2 (en) * | 1999-04-15 | 2010-02-26 | Crucell Holland Bv | Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
EP1130099A1 (en) * | 2000-02-25 | 2001-09-05 | Crucell Holland B.V. | Activated vitronectin as a marker of angiogenesis detected with phage antibodies |
DE60226896D1 (en) | 2001-12-17 | 2008-07-10 | Crucell Holland Bv | PREPARATION OF F (AB ') 2 FRAGMENTS IN TISSUE CELL |
-
2002
- 2002-12-17 DE DE60226896T patent/DE60226896D1/en not_active Expired - Lifetime
- 2002-12-17 SI SI200230701T patent/SI1456238T1/en unknown
- 2002-12-17 AU AU2002353662A patent/AU2002353662B2/en not_active Ceased
- 2002-12-17 ES ES02789019T patent/ES2307807T3/en not_active Expired - Lifetime
- 2002-12-17 WO PCT/NL2002/000841 patent/WO2003051927A2/en not_active Application Discontinuation
- 2002-12-17 US US10/499,298 patent/US20050048038A1/en not_active Abandoned
- 2002-12-17 CA CA2470579A patent/CA2470579C/en not_active Expired - Lifetime
- 2002-12-17 AT AT02789019T patent/ATE397019T1/en active
- 2002-12-17 DK DK02789019T patent/DK1456238T3/en active
- 2002-12-17 NZ NZ533332A patent/NZ533332A/en not_active IP Right Cessation
- 2002-12-17 EP EP02789019A patent/EP1456238B1/en not_active Expired - Lifetime
-
2008
- 2008-02-14 US US12/070,145 patent/US7537916B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5591828A (en) * | 1989-06-22 | 1997-01-07 | Behringwerke Aktiengesellschaft | Bispecific and oligospecific mono-and oligovalent receptors, the preparation and use thereof |
WO1993006217A1 (en) * | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
EP1108787A2 (en) * | 1999-11-26 | 2001-06-20 | Crucell Holland B.V. | Production of vaccines |
Non-Patent Citations (3)
Title |
---|
BOSHART M ET AL: "A VERY STRONG ENHANCER IS LOCATED UPSTREAM OF AN IMMEDIATE EARLY GENE OF HUMAN CYTOMEGALOVIRUS", CELL, MIT PRESS, CAMBRIDGE, MA,, US, vol. 41, no. 2, June 1985 (1985-06-01), pages 521 - 530, XP001079009, ISSN: 0092-8674 * |
FALLAUX F ET AL: "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses", HUMAN GENE THERAPY, XX, XX, vol. 9, no. 9, 1 September 1998 (1998-09-01), pages 1909 - 1917, XP002111070, ISSN: 1043-0342 * |
LEUNG S O ET AL: "The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES OCT 1999, vol. 5, no. 10 Suppl, October 1999 (1999-10-01), pages 3106s - 3117s, XP001149244, ISSN: 1078-0432 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002353662B2 (en) | 2009-04-23 |
DE60226896D1 (en) | 2008-07-10 |
CA2470579C (en) | 2012-03-06 |
ES2307807T3 (en) | 2008-12-01 |
WO2003051927A2 (en) | 2003-06-26 |
US20080166767A1 (en) | 2008-07-10 |
EP1456238B1 (en) | 2008-05-28 |
EP1456238A2 (en) | 2004-09-15 |
ATE397019T1 (en) | 2008-06-15 |
SI1456238T1 (en) | 2008-08-31 |
CA2470579A1 (en) | 2003-06-26 |
DK1456238T3 (en) | 2008-08-18 |
US20050048038A1 (en) | 2005-03-03 |
AU2002353662A1 (en) | 2003-06-30 |
US7537916B2 (en) | 2009-05-26 |
NZ533332A (en) | 2005-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL162648A0 (en) | Cellular compositions and methods of making and using them | |
EP1362093A4 (en) | Rapid production of monoclonal antibodies | |
WO2003051927A3 (en) | Production of f(ab')2 fragments in mammalian cells | |
AU2001294198A1 (en) | Cells producing antibody compositions | |
CA2442135A1 (en) | Methods to culture circovirus | |
NO20061470L (en) | Process for the preparation of gamma-carboxylated proteins | |
IT1293068B1 (en) | PROCEDURE FOR OBTAINING A HIGH CONCENTRATION COLLOIDAL SILICA SUSPENSION AND PRODUCT SO OBTAINED | |
AU1593001A (en) | Recombinant gelatin in vaccines | |
WO2002029083A3 (en) | Industrial-scale serum-free production of recombinant proteins in mammalian cells | |
HK166495A (en) | HIV-1 envelope muteins lacking hypervariable domains | |
CA2188165A1 (en) | Methods for proliferating and differentiating b cells, and uses thereof | |
CA2374003A1 (en) | Improved cellular uptake of bioactive agents | |
HUP0301766A2 (en) | Process for the preparation of latent antithrombin iii | |
AU4017501A (en) | Cell culture spinner flasks | |
PT1451302E (en) | In vitro reconstituted sheets of human corneal epithelium and method of producing the same | |
GB2351296A (en) | Keratinocyte stem cells | |
AU2001283132A1 (en) | Enhancement of industrial production by increasing substrate transport | |
AU2003273521A1 (en) | Production method of iturin a and its homologues | |
AU2001280368A1 (en) | Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy | |
AU2002337697A1 (en) | Pine cone extracts and uses thereof | |
WO2000073420A3 (en) | Creation of human tumorigenic cells and uses therefor | |
AU5045493A (en) | Process for preparing conjugates consisting of a specific binding partner and a carbohydrate-containing protein | |
BR9800928A (en) | Cosmetic material, and, process for preparing the same. | |
WO2003027242A3 (en) | Fas ligand | |
IT1302261B1 (en) | ENZYMATIC KINETIC RESOLUTION PROCESS OF 3-PHENYLGLYCIDATES FOR TRANSESTERIFICATION WITH AMINO-ALCOHOLS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002789019 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002353662 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 533332 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2470579 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2002789019 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10499298 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 533332 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 533332 Country of ref document: NZ |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |